HUTCHMED (China) Limited (HCM)

Market Cap	2.48B
Revenue (ttm)	602.20M
Net Income (ttm)	466.88M
Shares Out	859.30M
EPS (ttm)	0.53
PE Ratio	5.31
Forward PE	11.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,226
Open	14.20
Previous Close	13.75
Day's Range	14.18 - 15.00
52-Week Range	11.51 - 19.50
Beta	0.50
Analysts	Sell
Price Target	13.75 (-6.21%)
Earnings Date	Aug 7, 2025

About HCM

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,811
• Stock Exchange: NASDAQ
• Ticker Symbol: HCM
• Website: https://www.hutch-med.com

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Analyst Summary

According to one analyst, the rating for HCM stock is "Sell" and the 12-month stock price target is $13.75.

Price Target

$13.75

(-6.21% downside)

Analyst Consensus: Sell